Sutent Maintenance After Response to Taxotere

PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2007

Study Completion Date

November 30, 2012

Conditions
Prostate CancerHormone Refractory
Interventions
DRUG

Sunitinib (SU011248)

SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression

Trial Locations (4)

t4c 2h5

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

Vancouver Cancer Centre, Vancouver

N6A 4L6

London Health Sciences Centre, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Alberta Health services

OTHER

NCT00550810 - Sutent Maintenance After Response to Taxotere | Biotech Hunter | Biotech Hunter